RAS mutations in myeloid malignancies: revisiting old questions with novel insights and therapeutic perspectives
D Alawieh, L Cysique-Foinlan, C Willekens… - Blood Cancer …, 2024 - nature.com
NRAS and KRAS activating point mutations are present in 10–30% of myeloid malignancies
and are often associated with a proliferative phenotype. RAS mutations harbor allele …
and are often associated with a proliferative phenotype. RAS mutations harbor allele …
Impact of p53-associated acute myeloid leukemia hallmarks on metabolism and the immune environment
M Chomczyk, L Gazzola, S Dash, P Firmanty… - Frontiers in …, 2024 - frontiersin.org
Acute myeloid leukemia (AML), an aggressive malignancy of hematopoietic stem cells, is
characterized by the blockade of cell differentiation, uncontrolled proliferation, and cell …
characterized by the blockade of cell differentiation, uncontrolled proliferation, and cell …
Pathogenic GATA2 genetic variants utilize an obligate enhancer mechanism to distort a multilineage differentiation program
Mutations in genes encoding transcription factors inactivate or generate ectopic activities to
instigate pathogenesis. By disrupting hematopoietic stem/progenitor cells, GATA2 germline …
instigate pathogenesis. By disrupting hematopoietic stem/progenitor cells, GATA2 germline …